A new report from GlobalData UK indicates that the market for HER2-positive breast cancer treatments could grow from $6.4 billion in 2015 to $9.89 billion in 2025, a compound annual growth rate (CAGR) of 4.4%.
A new report from GlobalData UK indicates that the market for HER2-positive breast cancer treatments could grow from $6.4 billion in 2015 to $9.89 billion in 2025, a compound annual growth rate (CAGR) of 4.4%.
The report, which examines the HER2-positive treatment market in the United States, the United Kingdom, France, Germany, Italy, Spain, Japan, and China, indicates that the adjuvant and neoadjuvant settings of the market, which the report’s authors say will reach $4.96 billion by 2025, are likely to emerge as the main drivers of sales. The biggest sales driver is expected to be the monoclonal antibody pertuzumab (Roche’s Perjeta) used in first-line therapy for HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin) and docetaxel.
Because pertuzumab and the reference trastuzumab are believed to work in complementary ways to increase death of cancer cells, increased use of pertuzumab could help protect sales of Herceptin in a landscape with growing numbers of biosimilar options, the authors say. Perjeta will also extend the duration of treatment, contributing to higher sales numbers.
Max Bourgognon, healthcare analyst for GlobalData, explained the staying power of the monoclonal antibodies in the marketplace, saying, “The dynamism of the adjuvant and neoadjuvant markets has prompted many companies to position their products in these settings. However, many agents have failed to demonstrate clinical benefit over the currently cemented standard of care, meaning the adjuvant and neoadjuvant settings will remain an exclusive market for anti-HER2 monoclonal antibodies, hence constituting the most lucrative opportunity for biosimilar developments.”
The report also indicates that the anticipated launch of Puma Biotechnology's neratinib in late 2017 could create a new treatment setting for the treatment of HER2-positive breast cancer: the extended adjuvant setting, a currently underexplored area that could boom as additional drug manufacturers seek market share. Neratinib, a tyrosine kinase inhibitor (TKI), blocks signal transduction through the epidermal growth factor receptors HER1, HER2, an HER4. Puma Biotechnology says that it sees the potential for the oral treatment to be used in several additional indications, including gastric cancer. The drug was recommended for approval by the FDA's Oncologic Drugs Advisory Committee (ODAC) in May.
As promising as new TKIs may be, the report notes that there remains room for new products, and that patients who have TKI-resistant HER2-positive cancer remain an especially underserved segment of the patient population that will require innovative therapies to meet their needs.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.